SUMMARY
Oral cyclosporine was soon used as a key drug in the prevention of transplant rejectionS and also to treat autoimmune disease.6,7 Systemic cyclosporine was reported to be valuable in experimental models of uveitis8 and in sight-threatening posterior uveitis in man. 9 Topical cyclosporine was first used to prevent corneal graft rejection.lO,n Other indications for topical use in man include Mooren's ulcer,12 vernal keratoconjunctivitis,13 ligneous conjunctivi tis, 14 peripheral rheumatoid ulcerationlS and other ocular surface inflammatory disease. 16 The ameliora tive effects of topical cyclosporine in these inflam matory ocular surface disorders are readily explicable through direct effects on lymphocyte action.
Is the same spectrum of effects seen in domestic animals? Ocular surface inflammatory disease is seen in many domestic animals as discussed below. Cyclosporine has ameliorative effects in some of these diseases but not in all. The most interesting perspective from a comparative viewpoint is the beneficial effects of topical cyclosporine in canine keratoconjunctivitis sicca (KCS), with important implications for human Sjogren's syndrome patients. The mechanism of cyclosporine's lacrimogenic activ ity remains unclear, but there is no doubt that the drug does increase tear production in experimental animals, in companion animals and in man. Other questions remain with regard to the pharmacoki netics of topical cyclosporine from a theoretical aspect, and patient tolerance of different formula tions in practice.
A licensed product (Optimmune, 0.2% cyclospor ine ointment. Schering Plough, Welwyn, Herts, UK) is now available in the veterinary field for use in KCS and ocular surface inflammatory disease, but such a preparation has yet to reach the human pharmacy. For once veterinary ophthalmology can consider itself ahead of its human cousin! Eye (1997) 11,453-464 © 1997 Royal College of Ophthalmologists
MECHANISM OF ACTION OF CYCLOSPORINE
For a drug so widely used in human medicine, it may seem surprising that the mechanism of immunosup pression caused by cyclosporine is still imperfectly understood. Several clues as to the mechanism of drug action have come from studies investigating intracellular molecular interactions of cyclosporine.
Comparisons between cyclosporine, its immunosup pressive cousins FK-506 and rapamycin and non immunosuppressive analogues such as 506-BD and L-6835,818 have allowed researchers to determine which of these interactions are immunosuppressive.
It is now known that the major site of immunosup pressive drug action is the inhibition of lymphokine secretion by T lymphocytes. This reduction in production of a group of lymphokines including interleukins 2 and 3 (IL-2, IL-3), tumour necrosis factor alpha (TNF-a) and interferon-gamma is caused by the blockade of lymphokine gene tran scription. The inhibition of mRNA production is related to interference with the synthesis or transport of transcriptional promoters such as NF-AT.17 NF-AT is produced early in T cell activation and binds to regulatory regions upstream of genes coding for molecules such as IL_2.18 NF-AT is a subunit of a protein complex essential for the transcription of the IL-2 gene. It exists as a cytosolic component NF-ATc which, when dephosphorylated, can move into the nucleus where it binds to the IL-2 promoter region. This critical dephosphorylation of NF-ATc occurs under the influence of calcineurin and is prevented by cyclosporine. 19 The action of cyclosporine on calcineurin involves several intermediate steps. Cyclosporine binds to a cytosolic protein cyclophilin, one of a group of intracellular proteins now known as immunophilins. FK-506 and rapamycin bind to another immunophi lin known, rather unimaginatively, as FK binding protein (FKBP). While FKBP has no sequence homology with cyclophilin and does not bind cyclosporine, both cyclophilin and FKBP share peptidyl-prolyl cis-trans isomerase (PPI) activity. This isomerase action is critical in the folding of newly transcribed polypeptides and possibly also in protein stabilisation. Binding to these molecules or inhibition of their PPI effect cannot, however, be the mechanism of immunosuppression of cyclosporine or FK-506 since the non-immunosuppressive analogues also bind and act as PPI inhibitors?O It was hypothesised, however, that cyclophilin and FKBP have a role when bound to an intracellular kinase or phosphatase, forming a physiologically regulated enzyme complex. The action of cyclospor ine, FK-506 or rapamycin cannot, however, be by preventing complex formation, since the concentra tion of drug required for immunosuppression is much D. L. WILLIAMS smaller than the concentration needed to block all available cyclophilin or FKBP molecules. Instead the drugs would, in this model, exert their actions by forming a complex which alters enzyme activity. Cyclosporine-cyclophilin and FK-506-FKBP com plexes have indeed been shown to bind to, and inhibit, the phosphatase calcineurin?l Since NF-ATc dephosphorylation is thus prevented the molecule cannot be transported into the nuclear compartment where it would have access to transcriptional regulating domains upstream of cytokine genes. 22 It is in this rather convoluted manner that cyclosporine has its action inhibiting lymphocyte activity.
Cyclosporine also interacts with calmodulin, bind ing to a hydrophobic pocket on the molecule, a feature shared with a number of calmodulin antago nists.23 Given that calcineurin is regulated by calmodulin, the calmodulin-cyclosporine interaction may be important in drug action. Since, however, calmodulin binding is a characteristic of non-immu nosuppressive as well as immunosuppressive cyclo sporine analogues there is still debate over its role in the drug's immunomodulatory actions.
Many of the immunomodulatory effects of cyclo sporine relate to inhibition of lymphokine produc tion, although other areas of lymphocyte activity are also affected. Cyclosporine inhibits the release of granule-associated serine esterase important in cyto toxic T lymphocytes and particularly in polymorpho nucleocytes? 4 Activation-driven apoptosis is also inhibited?S Significantly both of these involve intracellular calcium influx.
The relevance of all this basic science to the clinical use of topical cyclosporine might well be questioned. Yet, as will be discussed below, another of the key therapeutic effects of topical cyclosporine is to increase tear production. At present our understanding of the mechanisms of lacrimogenesis by cyclosporine are at the same stage that mechan isms of immunosuppression were 10 years ago. The myriad of molecular interactions of the drug show the difficulty of pinpointing the site of action of cyclosporine with regard to lacrimogenesis. Further research is needed using cyclosporine and its analogues, those both with and without immunomo dulatory action, to probe mechanisms of lacrimation in the same way as they have been used to map mechanisms in T cell function.
TOPICAL CYCLOSPORINE AS A LACRIMOGENIC AGENT
This second action of cyclosporine might come as rather a surprise after the emphasis on immunosup pressive effects. Cyclosporine increases tear produc tion in dogs with KCS ( Fig. 1) , a disease similar to the ocular manifestations of Sjogren's syndrome in man. One might suppose that the initial reason for Kaswan was the first to show that topical cyclosporine has a marked lacrimogenic effect in the dog30 and these results have been repeated in other species: topical cyclosporine has been used successfully in horses with KCS3l,32 and in cats in this author's experience, although KCS is rare in both these species.
The lacrimogenic effect occurs not only in dogs with KCS but also in normal animals. Fig. 2 shows Schirmer tear test readings in dogs treated with 0.2% cyclosporine ointment (Optimmune, Schering Plough) twice daily in the present author's study of dogs with chronic superficial keratitis?3 These animals exhibited immune-mediated corneal pathol ogy but no lacrimal gland abnormalities and thus had normal tear production. Schirmer tear test readings, normally 18.3::!:: 3.4 mm min-1 in the 30 dogs involved, increased by 5.7 mm while cyclosporine was used but no significant change was observed with the use of topical 0.1 % dexamethasone. These differences were significant during treatment as demonstrated by an analysis of variance presented as p values in Fig. 2 . Fig. 3 shows Schirmer tear test Time (weeks) readings in 10 dogs presented to our hospital recently with KCS. In 7 dogs with low but measurable lacrimation, cyclosporine gave significant increases in tear production. Two animals with zero Schirmer readings showed no increase in lacrimation with cyclosporine while one animal with no measurable tear production did respond. This small group of dogs are typical of canine KCS cases, where the majority respond well but a small number fail to respond. It is presumed that the non-responders are cases in which gland atrophy or scarring has progressed to a stage in which no functional lacrimal tissue remains. Even so there are a number of dogs with zero Schirmer readings in which cyclosporine produces measurable tearing either immediately after commencing treatment, or more usually after a period of twice daily medication. These results confirm the findings of Kaswan's group3 0 who demonstrated an increase in Schirmer tear test readings in dogs with KCS from 3.5 ± 4.6 mm min-1 before treatment with 2% topical cyclo sporine to 12.5 ± 6.5 mm minI. Normal beagles with readings of 19.2 ± 3.0 mm min-1 showed an increase to 25.8 ± 2.9 mm min-l. These results show that cyclosporine has lacrimogenic effects in the normal as well as the KCS-affected animal. Other evidence suggests that the lacrimogenic actions do not relate directly to an immunosuppressive action of cyclo sporine, since other immunosuppressive agents given topically do not result in an increase in lacrimation.
Having said that, there is likely to be an ameliorative effect on tear production by reducing autoimmune lacrimal gland destruction in cases in animals and man where this is the cause of KCS. The MRLlMP-1pr/1pr mouse with its defective lympho cytic apoptosis3 4 develops an autoimmune disease with lymphadenopathy, glomerulonephritis and ser ologic disturbances together with ocular and lacrimal gland pathology which is a good model of Sjogren's syndrome. One study reported cyclosporine to worsen lacrimal gland pathology in these mice with CD4+ lymphocytes replaced with CD8+ cells even where systemic autoimmune pathology was amelio rated? 5 Here tear production was reduced by cyclosporine therapy by implant. Similar results were shown for salivary gland immunopathology in human Sjogren's syndrome, where the drug signifi cantly worsened gland infiammation?6 A more recent report finds systemic cyclosporine to be efficacious in reducing severity of both ocular and lacrimal gland lesions in MRLlMP-1pr/1pr mice although tear volumes were not measured in this study. 3 7 The relative roles of immunosuppression and direct lacrimogenesis in ameliorating keratocon junctivitis sicca in these mice are unclear, but the action of cyclosporine in normal dogs would appear to suggest that a direct effect is more likely to be D. L. WILLIAMS occurring rather than one secondary to immunomo dulation of infiammatory disease.
While Kaswan initially used 2% cyclosporine in olive oil, subsequent American studies used other oils as diluting vehicles and reduced the cyclosporine concentration to 1.5% and then 1 %?8 The present author began investigating the use of topical cyclo sporine in 1990 and found that 0.2% cyclosporine in corn oil appeared to be as lacrimogenic as 2 % solution. This prompted a small dose-response study with somewhat surprising results (Fig. 4) . Taking the mean values of improvement in Schirmer tear test reading for a group of dogs gives a standard dose-response curve (heavy line, Fig. 4 ). But for individual animals there seems a sharp cut-off between maximal improvement and no response whatsoever. The concentration at which this cut-off occurs seems different for each dog, resulting in the large error bars in a standard dose-response curve at around these concentrations. The action of topical cyclosporine in the majority of dogs at one-tenth of the concentration originally used is now widely recognised, and now 0.2 % ointment is licensed and marketed for veterinary use.
What do these findings in normal and KCS affected dogs suggest concerning mechanisms under lying the lacrimogenic action of cyclosporine? Initial suggestions that cyclosporine acted predominantly by reducing the lymphocytic infiltrate in canine KCS are unlikely to be correct. Firstly the rapid lacrimogenic action of the drug occurs faster than resolution of the infiammatory infiltrate in affected glands. Secondly the drug increases tear production in normal animals where a pathological lacrimal gland lymphocytic infiltrate does not occur. This does not, however, preclude lymphocytes from playing a role in lacrimal gland regulation. A wide variety of peptide hor mones and neuropeptides influence lacrimal gland function, and cytokines from lymphocytes within the normal lacrimal gland may play an important part in lacrimal stimulation. Cyclosporine may also affect hormonal interac tions with lacrimal tissue. The drug increases prolactin binding to lacrimal tissue? 9 in contrast to the situation in lymphocytes where cyclosporine competitively inhibits prolactin binding. 4 o Prolactin has been shown to inhibit peroxidase release in lacrimal tissue, an indicator of lacrimal secretion. 4 1 Cyclophilin is a ligand for prolactin and as such an interaction between cyclosporine, prolactin and the lacrimal acinar prolactin receptor may be responsible for the lacrimogenic effects of the drug. 4 2 Cyclospor ine, FK-506 and rapamycin have been shown to inhibit prolactin gene expression in the pituitary gland, 4 3 but the apparent lack of systemic penetra tion of topical cyclosporine renders it unlikely that the pituitary is the site of action of topical cyclo sporine. Inhibition of local prolactin production may, however, be important in drug-induced lacrimogen esis.
THE PHARMACOKINETICS OF TOPICAL CYCLOSPORINE
Inflammatory diseases of the ocular surface are the obvious indications for topical cyclosporine therapy. Drug penetration to the cornea and conjunctiva occurs readily following topical administration. The lipophilicity of cyclosporine renders the cornea a reservoir for the drug. As discussed above, canine KCS is another prime indication for the use of topical cyclosporine. Effects on lacrimation clearly require penetration of the drug to the lacrimal gland but the lipophilic nature of the molecule would facilitate such local tissue distribution. More complex are the problems associated with penetration of cyclosporine into the intraocular compartment for use in uveitis and the systemic spread of topically applied drug. Cyclosporine in an oil base is retained by the cornea as a reservoir; this effect is accentuated by application in an ointment base. 44 But is topically applied drug absorbed into the intraocular or systemic circulating compartment? While some reports document negligible serum levels of drug following topical application, 4 5 other workers found significant circulating levels after topical applica tion. 4 6 These differences are likely to relate to the volume of fluid applied to the eye in small experi mental animals, where considerable nasolacrimal overflow can give systemic absorption after mucosal penetration. These effects are likely to have flawed experiments in which topical cyclosporine was 457 reported to have been efficacious in treating experi mental posterior segment inflammatory disease. 4 7 Similar problems can be seen comparing results documenting trans corneal penetration into intraocu lar compartments. Some workers find low levels of drug in intraocular compartments after topical administration 4 8 -5 o while others report significant drug levels in aqueous. 5 1 . 5 2 Some differences relate to the vehicle in which the drug is presented while others are frankly inexplicable.
Variations in transcorneal cyclosporine penetra tion are, however, important if the drug is to be used for intraocular immunosuppression. Olive oil and corn oil appear to give little trans corneal penetration. Alpha-cyclodextrin has been shown in one in vivo human study to give therapeutic levels in aqueous humour after five applications one day before cataract surgery at which samples of aqueous were taken. 5 3 The findings of this study are not corrobo rated by an in vitro investigation which failed to demonstrate increased transcorneal permeability with alpha-cyclodextrin as the vehicle compared with corn oil. Delivery of cyclosporine in liposomes alone or liposomes incorporated in collagen shields gave good intraocular penetration when compared with cyclosporine in corn oil in an in vivo rabbit model. 5 4 At present topical cyclosporine is not regularly used to combat intraocular inflammation in the fields of either human or veterinary ophthalmology. Yet investigations of its use to combat corneal transplant rejection and in ocular surface inflammatory disease have been widespread.
TOPICAL CYCLOSPORINE IN CORNEAL ALLOGRAFT REJECTION
Corneal transplants are the most successful solid tissue grafts, with HLA tissue matching generally being considered non-essential. Nevertheless, rejec tion remains the most common cause of graft failure. 55 High-risk keratoplasty involving a vascu larised donor bed or as a consequence of previous graft failure requires intensive anti-inflammatory therapy. Topical corticosteroids are used both prophylactically and in the management of a rejec tion episode: systemic treatment may be added by oral medication or in an intravenous pulse regime. Adding topical cyclosporine to the anti-inflammatory regime is an important option in these high-risk situations. Several experimental models of high-risk kerato plasty have been reported. In one model full thickness skin grafts were exchanged between mouse strains after corneal grafting. Topical cyclo sporine in a water-soluble galenic form dissolved in ethanol and chremophor was given five times daily. Mean survival time in treated grafts was 37 days compared with 26 days in control animals.56 This report used 5% cyclosporine while a previous study using a 1 % concentration showed no effect prolong ing graft survival.57 This is a somewhat surprising result given that the group showed the same concentration preventing rejection 1 year later in a different model without skin grafting.58 Giving 5% cyclosporine five times daily, however, results in an overall administration of 3 mg/kg per day, a dose which could give systemic immunosuppression. Foets and colleagues 4 5 discuss the relative importance of systemic versus local immunosuppression in their study of graft survival with topical cyclosporine. Given that cyclosporine administration in one eye failed to prevent graft rejection in the fellow eye, these workers considered that local and not systemic immunosuppression was occurring here, although plasma levels of cyclosporine were at immunosuppressive levels.
. Other workers have shown that cyclosponne dissolved in the penetration enhancer azone acts to suppress graft rejection, although their study did not compare cyclosporine in oil with cyclosporine in azone. 59 Similarly corneal allograft survival is pro longed with cyclosporine delivered in liposomes in the rat, with that particular study showing an increased survival of liposome-incorporated cyclo sporine com�ared with the same dose � f cyclospor�ne in olive oil. 6 Even small advantages gIven by vaned delivery systems are potentially important given the difficulty in providing adequate medication in high risk allografts. Sometimes systemic cyclosporine treatment is the only sure way of preventing . . 61 reJectIOn.
TOPICAL CYCLOSPORINE IN OCULAR SURFACE INFLAMMATORY DISEASE
In veterinary medicine the main indication for the use of cyclosporine is canine KCS, where the drug's lacrimogenic effects outweigh anti-inflammatory actions in importance. Ocular surface inflammatory disease is also an indication for the use of topical cyclosporine, although canine KCS was initially t�e only indication mentioned on the drug data sheet III the UK. In the dog and cat two severe corneal inflammatory conditions occur: chronic superficial keratitis (CSK) in the dog (Fig. 5 ) and feline eosinophilic keratoconjunctivitis in the cat (FEKC) (Fig. 6) . My doctoral studies involved immunocyto chemical and histochemical characterisation of the former as well as evaluation of treatment regimes using topical dexamethasone and topical cyclospor ine. The corneal lesion of CSK involves superficial stromal lymphocytic infiltration, with the predomi nant cell type being the CD4+ lymphocyte, many cells producing )'-interferon.62 Thus the disease would seem the ideal candidate for topical cyclos porine therapy. Indeed it is: my studies sho � ed equivalent ameliorative actions on corneal leSIOns produced by topical cyclosporine and the standard therapy for the condition, topical steroid? 3 A placebo controlled trial was not attempted for ethical reasons and since such a trial had already been reported showing that it was the drug and not vehicle which had the anti-inflammatory effects. 63 Mooren's ulcer is not a recognised disease in the pet cat or dog population, neither are rheumatoid related peripheral corneal melts. On occasion dogs may present with apparently comparable disease (Fig. 7) but numbers of affected animals are so small that more than anecdotal reports are not possible. One would expect, nevertheless, that topical cyclo sporine would be valuable in such cases, as it has been shown to be in human Mooren's ulcer and peripheral melts.6 4 •65 Scleritis is seen in the dog, although not commonly (Fig. 8) . A different spec trum of disease presentation is seen in the dog as compared with man: ischaemogenic vasculitis is exceptionally rare and thus sequelae such as scler omalacia perforans are almost never seen. Never-66 . I I . theless, as is the case with man, toplca cyc osponne TOPICAL CYCLOSPORINE THERAPY can be useful in the treatment of canine scleritis and episcleritis. A more common ocular surface disease in the dog where cyclosporine is indicated is canine plasmacytic conjunctivitis. 6 7 While the cell pheno type, as demonstrated immunocytochemically here, is again predominantly the CD4+ lymphocyte, the term plasmacytic conjunctivitis remains since the original histology showed a mixed lymphocytic plasmacytic infiltrate. In this disease, as with CSK, long-term steroid treatment is indicated if cyclospor ine is not used. The deleterious effects of steroid induced glaucoma and cataract, as seen in man, do not appear to occur in dogs, even on life-long topical steroid treatment. However, subclinical adrenocor tical suppression has been noted on long-term topical ocular steroid treatment in the dog. 6 8 A change to topical cyclosporine might thus be appropriate given that to date no clinical systemic effects have been detected.
D. L. WILLIAMS
Note added in proo!, Since the submission of this paper, the finding of reduction in lymphocyte proliferative responses in dogs on long-term treat ment with topical 2% cyclosporine has been reported (Gilger BC, Andrews lA, Wilkie DA, Lairmore MD. Vet Comp OphthalmoI1996;6 : 125-130). Initial find- 
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ings from our laboratory suggest that the use of topical 0.2 % cyclosporine ointment does not cause this suppression, although our studies have yet to be completed.
There is no human equivalent of chronic super ficial keratitis, but FEKC has been suggested as a potential spontaneous animal model for vernal keratoconjunctivitis (VKC). 6 9 There is some debate within the veterinary ophthalmology field over the efficacy of cyclosporine in this condition. The present author has not found cyclosporine to be particularly useful in FEKC while others have reported good therapeutic effects ? O Two problems occur with this disease. Firstly the incidence of the condition is significantly lower than that of canine CSK; it is thus a greater problem to amass a suitable number of cats for a randomised clinical trial. Secondly it may be that two diseases are presenting with similar clinical signs. While in some lesions eosinophils predominate and thus the term eosinophilic keratitis is appro priate, in other animals a wider spectrum of inflammatory cells infiltrate the conjunctiva and cornea and the term proliferative keratitis is pre ferred by some to include these animals. Consider able further investigation of this disease is required before comparative therapeutic implications can be defined.
Whatever the potential value of feline eosinophilic or proliferative keratitis as a spontaneous animal model for vernal keratoconjunctivitis, it is clear that topical cyclosporine is extremely effective in human VKC. 71 While the number and size of giant papillae were not changed during treatment with 2 % cyclo sporine dissolved in corn oil, corneal punctate staining and Tarrantas' dots were markedly reduced as was photophobia. The mechanism of action of cyclosporine in VKC is unclear. It may be that cyclosporine has a direct effect on mast cells or perhaps it is more likely that the T-Iymphocyte dependent mast cells known to be increased in VKC 72 are affected in an indirect manner through inhibition of helper T cell action. Another study showed that, while 75% of children with VKC showed persistent improvement on cyclosporine therapy and 58% were symptom-free on treatment, only 25% were still free of the disease 2 months after treatment was discontinued. 13 This drop off in symptom relief after treatment cessation was also shown in our study of cyclosporine in CSK : after 2 months 30% of dogs were still symptom free. 33 The time to lesion recurrence is illustrated in the actuarial survival plot showing maintenance of a clear cornea after withdrawal of daily treatment (Fig. 9 ). An average of 45 days elapse after treatment cessation before lesion recurrence. Thus in both human and canine disease continual and potentially life-long treatment is required.
Such long-term treatment must, of course, raise questions regarding potential side effects. Local irritation was noted in a number of dogs when cyclosporine was used at 2 % dissolved in olive oil, but the present author, using the drug equally effectively at 0.2% in corn oil or in an ointment formulation, saw no adverse effects over and above those transient irritative effects noted when any topical preparation is given to some dogs. Experi mental studies on potential cyclosporine toxicity found superficial epithelial cell cratering and reduc tion of epithelial cell microvilli with 0.075% cyclo sporine given every 30 minutes over a 5 hour period, although the penetrating agent alpha-cyclodextrin was included in the application so that it is somewhat difficult to assess which agent had the deleterious effect. 73 The influence of topical cyclosporine in olive oil on corneal epithelial permeability has been determined in an in vivo study using human volunteers ? 4 Prolonged (>1 hour) ocular irritation was noted with the 2 % cyclosporine formulation but also with olive oil alone. Experimental subjects developed punctate keratopathy which resolved after 24 hours. Epithelial permeability increased 7 times after application but again the cause of this change was the vehicle and not the agent itself. While the trials undertaken by Allergan showed untoward irritative effects with cyclosporine in their vehicle, the ointment base used by Schering-Plough for Optimmune, the veterinary product, appears to have had minimal deleterious effects.
With regard to systemic effects, generalised immunomodulation would depend on systemic absorption of the drug from topical drops. As discussed above there has been some controversy over the amount of drug absorbed after topical administration and changes in circulating lymphocyte activity and dynamics on topical treatment are currently under investigation in our laboratory. The key point to note at present is that no deleterious systemic signs have been noted in any of the D. L. WILLIAMS considerable number of dogs on 2% or 0.2% topical treatment since cyclosporine began to be used by the veterinary ophthalmic community worldwide in 1990.
The effect of topical cyclosporine on herpetic disease of the external eye might well be of concern. It is known that topical steroid increases the severity of epithelial herpetic disease both in humans and in the cat, where feline herpes virus causes similar lesions to those seen in man ? 5 Stromal extension with potential for melting and corneal perforation is possible unless concurrent antiviral medication is given. When combined cyclosporine-trifluorothymi dine treatment was given to animals in a rabbit experimental model of herpes simplex viral kerati tis, stromal disease severity was considerably reduced, while anti-viral medication alone had little effect on what is now known to be an immune mediated lesion. 7 6 Cyclosporine without antiviral cover was reported to result in increased epithelial disease, although data substantiating this claim were not shown. In the aforementioned study animals had been systemically sensitised to herpes simplex virus prior to intra-stromal challenge with virus. Iritis occurred in all animals and the intraocular inflammation was not ameliorated by the topical steroid. A second paper used a rabbit model with primary topical infection onto an abraded cornea. 77 Here systemic cyclosporine potentiated stromal disease without exacerbating epithelial lesions, but given that animals would have been systemically immunosuppressed, the relevance of these findings to the topical use of cyclosporine is difficult to gauge. The prevalence of viral ocular surface disease in the dog is unknown: punctate ulcerative keratopathy in the dog (Fig. 10) is seen as an ocular surface inflammatory disease in which some animals are responsive to trifluorothymidine, suggesting a viral aetiology, while other animals do not respond to antiviral medication. Again cyclosporine is effective in ameliorating corneal signs in these latter animals. Given that long-term topical cyclosporine must to some degree compromise the immune status of the ocular surface are there deleterious effects increasing ocular surface bacterial flora? One paper, again from Kaswan's group, has examined results of bacterial isolation from over 30 dogs with KCS before and during topical cyclosporine treatment. 78 Eyes respond ing well to treatment showed a reduction in bacterial isolation from the ocular surface. Eyes not responding to treatment with an increase in Schirmer tear test readings did not show a change in ocular surface bacterial population, indicating on the one hand that it was increased lacrimation rather than a direct anti biotic action of the drug which reduced bacterial isolation in responding dogs and on the other that cyclosporine-mediated ocular surface immunomodula tion without increased lacrimation does not alter the ocular surface bacterial population. The antimycotic actions for which cyclosporine was initially devel oped 79 did not appear to reduce ocular surface yeast or fungal populations, but neither were these organisms recovered in greater numbers as might be expected in an immunosuppressive environment.
TOPICAL CYCLOSPORINE FOR HUMAN USE: SOME CONCLUDING COMMENTS Topical cyclosporine would appear, then, to be a potent specific immunomodulator and lacrimogen widely and successfully used in the veterinary world both for canine KCS and for ocular surface inflammatory disease. Why then. it must be asked, has a commercial topical cyclosporine preparation hot been marketed for human use? Regulations regarding development of novel human medications are likely to be more stringent and thus restrictive than for veterinary products for the small animal market. The successful use of cyclosporine formu lated in olive oil in the veterinary market as a 'home made' product presumably eased the drug's passage to the market as a licensed veterinary preparation. Such widespread use of an unlicensed preparation would be far less acceptable in the human field. The initial problems experienced by Allergan with ocular irritation in early clinical trials may well have dampened enthusiasm for the drug, although these are likely to be related to the vehicle and not the drug itself. Although topical cyclosporine was first used in the veterinary field as a home-made preparation in various oil bases, the introduction of a commercial product (Optimmune, Schering Plough) has brought with it standards of safety, efficacy and shelf-life. While cyclosporine has been seen by the veterinary ophthalmic community as nigh on a miracle cure for KCS the drug has not had the same take-up in Sjogren's syndrome, the human condition analogous in many ways to canine KCS.
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So to conclude, given that topical cyclosporine is so widely used in canine KCS, what are the opportu nities for using the drug in human dry eye and particularly in Sjogren's syndrome? Only a small number of studies on human subjects have been published. Laibovitz and colleagues treated 26 patients with KCS in a randomised double-masked placebo controlled single-crossover design study with a 2 week intertreatment washout period using 1 % cyclosporine ointment (Refresh, Allergan) twice daily. Rose Bengal staining scores, as measured by the Bijsterveld method, 80 were 55% improved in the group on cyclosporine after 1 week of treatment and improved to 85 % above baseline after 6 weeks. The placebo group improved to 60% above baseline but cyclosporine results were statistically better at p<0 . 05 . Tear film breakup times were also signifi cantly improved as was tear lactoferrin and Schirmer tear test readings. In the washout period symptoms did not return to baseline values and thus only 9 patients met inclusion criteria for the second treat ment period in this tria1. 81 Ironically of the 7 patients noting some intolerance to the medication, while 5 described itching or burning, 2 complained of over tearing! The present author has seen the same problem in dogs treated for mild canine KCS in which the problem turned from that of a dry eye to that of epiphora! Another stringently controlled trial of 2 % cyclosporine in olive oil compared 15 patients treated with cyclosporine with 15 given vehicle alone. Again 2 months of treatment gave significant improvements in tear film breakup time and Rose Bengal staining, although interestingly Schirmer-1 test results were not significantly changed (p> 0 . 05) . These authors concluded that cyclosporine modu lated goblet cell function in KCS associated with secondary Sjogren's syndrome. 82 This is, in the present author's opinion, an incorrect conclusion, but nevertheless the bottom line, if one might put it that way, is that topical cyclosporine is valuable in the treatment of the ocular signs associated with Sjogren's syndrome.
Surely from both these studies as well as from the wealth of veterinary experience there should be ample reason for further large trials and the rapid develop ment of a commercial preparation for the human ophthalmic market? Patients wih diseases as diverse as Sjogren's syndrome, Mooren's ulcer and vernal keratoconjunctivitis would benefit, as have our dogs with KCS and CSK. It is hoped that this comparative review will speed that development process.
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